Navenibart - matching placebo
Sponsors
Astria Therapeutics Inc.
Conditions
Hereditary Angioedema
Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema - ALPHA-ORBIT
RecruitingCTIS2025-521660-35-00
Start: 2025-09-11Target: 53Updated: 2026-01-26
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE
Not yet recruitingCTIS2025-521142-22-00
Target: 17Updated: 2026-02-10